BSE Live
Oct 01, 16:01Prev. Close
1078.55
Open Price
1078.45
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 01, 15:56Prev. Close
1079.40
Open Price
1078.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1113.00 (1)
Profit & Loss account of Jubilant Pharmova (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 7,192.10 | 6,644.80 | 6,219.30 | 6,059.17 | 5,963.88 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 7,192.10 | 6,644.80 | 6,219.30 | 6,059.17 | 5,963.88 | |
Total Operating Revenues | 7,234.50 | 6,702.90 | 6,281.73 | 6,130.16 | 6,098.54 | |
Other Income | 56.80 | 68.70 | 38.33 | 11.29 | 17.64 | |
Total Revenue | 7,291.30 | 6,771.60 | 6,320.06 | 6,141.45 | 6,116.17 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 1,985.30 | 1,821.30 | 1,666.41 | 1,348.70 | 1,348.75 | |
Purchase Of Stock-In Trade | 297.10 | 241.20 | 252.22 | 201.62 | 167.63 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FGWIP And Stock In Trade | 34.60 | 78.20 | -40.70 | -62.32 | 19.63 | |
Employee Benefit Expenses | 2,267.90 | 2,216.00 | 2,166.02 | 2,043.39 | 1,922.88 | |
Finance Costs | 240.30 | 272.30 | 188.20 | 145.49 | 184.10 | |
Depreciation And Amortisation Expenses | 368.60 | 381.90 | 554.03 | 381.70 | 348.95 | |
Other Expenses | 1,475.90 | 1,445.40 | 1,461.53 | 1,442.44 | 1,243.18 | |
Total Expenses | 6,669.70 | 6,456.30 | 6,247.71 | 5,501.02 | 5,235.12 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 621.60 | 315.30 | 72.35 | 640.43 | 881.06 | |
Exceptional Items | 359.50 | -168.90 | -56.82 | 0.00 | -21.23 | |
Profit/Loss Before Tax | 981.10 | 146.40 | 15.53 | 640.43 | 859.82 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 213.20 | 202.60 | 181.09 | 172.55 | 269.91 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | -68.90 | -104.80 | -88.42 | 44.88 | 27.31 | |
Other Direct Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 144.30 | 97.80 | 92.66 | 217.43 | 297.22 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 836.80 | 48.60 | -77.13 | 423.00 | 562.61 | |
Profit/Loss From Continuing Operations | 836.80 | 48.60 | -77.13 | 423.00 | 562.61 | |
Profit/Loss For The Period | 836.80 | 48.60 | -77.13 | 423.00 | 824.36 | |
Minority Interest | 3.10 | 4.40 | 3.90 | 0.92 | 0.26 | |
Consolidated Profit/Loss After MI And Associates | 839.40 | 77.10 | -60.98 | 413.94 | 835.87 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 53.00 | 5.00 | -4.00 | 26.00 | 52.00 | |
Diluted EPS (Rs.) | 53.00 | 5.00 | -4.00 | 26.00 | 52.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 79.60 | 79.60 | 79.64 | 79.64 | 0.00 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
20.07.2025
16.06.2025
30.07.2025
Jubilant Pharmo Consolidated June 2025 Net Sales at Rs 1,900.70 crore, up 9.76% Y-o-Y
30.07.2025
Jubilant Pharmo Standalone June 2025 Net Sales at Rs 59.50 crore, down 64.31% Y-o-Y
16.05.2025
Jubilant Pharmo Consolidated March 2025 Net Sales at Rs 1,928.80 crore, up 9.68% Y-o-Y
16.05.2025
Jubilant Pharmo Standalone March 2025 Net Sales at Rs 217.30 crore, up 5.59% Y-o-Y
18.01.2021
Jubilant Life Sciences Q3 PAT seen up 14.9% YoY to Rs. 238 cr: Prabhudas Lilladher
12.07.2019
Jubilant Life Sciences Q1 PAT may dip 10.4% YoY to Rs. 181.4 cr: Prabhudas Lilladher
12.04.2019
Jubilant Life Sciences Q4 PAT seen up 36.3% YoY to Rs. 211.2 cr: Prabhudas Lilladher
11.01.2019
Jubilant Life Science Q3 PAT seen up 13.8% YoY to Rs. 241.8 cr: ICICI Direct